ALK and laryngotracheoesophageal cleft: Beyond established targets like EGFR mutations and ALK gene fusions, other alterations, such as ROS1 gene fusions, are increasingly recognized as predictive biomarkers, thereby broadening the range of patients eligible for targeted LC therapies [5].